Minatogawa, Hiroko http://orcid.org/0000-0002-5836-8305
Izawa, Naoki
Nakajima, Takako Eguchi http://orcid.org/0000-0002-4589-2335
Article History
Received: 10 April 2024
Revised: 26 April 2024
Accepted: 29 April 2024
First Online: 15 May 2024
Competing interests
: NI reports grant from Taiho Pharmaceutical Co., Ltd., TEN reports grants from Sumitomo Dainippon Pharma Co., Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Sanofi K.K., Nippon Kayaku Co., MSD K.K., and Eli Lilly Japan K.K.; and reports personal fees from Thyas Co. Ltd., Rebirthel Co., Ltd., Japan Clinical Research Operations, Sumitomo Dainippon Pharma Co., Boehringer Ingelheim, Bristol-Myers Squibb, Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Amgen, Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Sanofi K.K., Novartis Japan, Nippon Kayaku Co., MSD K.K., Eli Lilly Japan K.K., Bayer Yakuhin, Pfizer Japan Inc., Daiichi, Sankyo Co., Yakult Honsha Co., Nipro Co, Merck Serono Co., AstraZeneca, IQVIA, and GlaxoSmithKline. All other authors declare no competing interests.